Serum amyloid-A (SAA) is an acute phase protein, synthesized by the liver and previously investigated as a marker of disease activity in many rheumatologic disorders. Its significance in Behçet’s disease (BD), a chronic inflammatory disorder at the crossroad between autoimmune and autoinflammatory syndromes, is still unraveled. Our aim was to assess the role of SAA levels as a potential marker of disease activity in patients with BD. According to our findings, the occurrence of oral aphthosis, neurological impairment, and ocular disease is significantly associated with SAA serum levels higher than 30, 50, and 150 mg/L, respectively. We also suggest that increased SAA levels might identify a thrombotic risk in BD with previous or concurrent vascular involvement
Vitale, A., Rigante, D., Lopalco, G., Brizi, M.g., Caso, F., Franceschini, R., et al. (2014). Serum amyloid-A in Behçet's disease. CLINICAL RHEUMATOLOGY, 33(8), 1165-1167.
Scheda prodotto non validato
Scheda prodotto in fase di analisi da parte dello staff di validazione
|Titolo:||Serum amyloid-A in Behçet's disease.|
|Citazione:||Vitale, A., Rigante, D., Lopalco, G., Brizi, M.g., Caso, F., Franceschini, R., et al. (2014). Serum amyloid-A in Behçet's disease. CLINICAL RHEUMATOLOGY, 33(8), 1165-1167.|
|Appare nelle tipologie:||1.1 Articolo in rivista|